87 completed, 35 terminated, 26 recruiting, 19 active not recruiting. 113 Phase 2, 62 Phase 1, 18 Phase 3, 16 Not applicable, 4 Early Phase 1.
Follow Mesna: new trials by email Literature Review of Mesna trials Research Report on Mesna
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 70 | 2026-10-03 | 2026-08-28 |
| Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma Cyclophosphamide, Fludarabine, Mesna - Pediatric Osteosarcoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 41 | 2026-09-01 | 2026-09-01 |
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
| A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC CC-38, Pembrolizumab, Cyclophosphamid - Metastatic Colorectal Cancer, Prostate Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | CuraCell TX AB | 12 | 2025-11-13 | 2026-06-22 |
| TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Thymoglobulin, Cyclophosphamide, Fludarabine - Hematologic Malignancy | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 30 | 2025-09-25 | 2026-06-02 |
| Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation Cytarabine IT, hydrocortisone, Cisplatin - CNS Embryonal Tumor, CNS, Medulloblastoma | Early Phase 1 | Recruiting | C17 Council | 15 | 2025-09-23 | 2026-07-14 |
| CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia Fludarabine, Cyclophosphamide, Mesna - Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 25 | 2025-05-21 | 2026-03-25 |
| CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia Fludarabine, Cyclophosphamide, Mesna - Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 30 | 2025-04-28 | 2026-05-19 |
| CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) CER-1236, Cyclophosphamide, Fludarabine - AML, Acute Myeloid Leukemia | Phase 1 | Recruiting | CERo Therapeutics Holdings, Inc. | 18 | 2025-04-07 | 2026-10-21 |
| Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma LN-144, Cyclophosphamide, Mesna - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 | Withdrawn | James Isaacs, MD | 2024-12-02 | 2025-06-05 | |
| Allo HSCT for High Risk Hemoglobinopathies Alemtuzumab, Total Body Irradiation, Cell Infusion - Graft Failure, Sickle Cell Disease | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 62 | 2024-11-19 | 2026-06-04 |
| CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies Fludarabine, Cyclophosphamide, CD70-CAR T cell infusion (Autologous) - Hematologic Malignancy, ALL, Childhood | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 18 | 2024-10-16 | 2026-01-23 |
| High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam - Splenomegaly, Myelofibrosis | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-10-01 | 2026-09-16 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma ADI PEG20, Ifosfamide, Radiotherapy - Soft Tissue Sarcoma, Sts | Phase 1 | Terminated | Washington University School of Medicine | 6 | 2024-03-14 | 2026-09-03 |
| Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 60 | 2024-02-14 | 2026-08-31 |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT) - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 313 | 2023-12-08 | 2026-08-17 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| Virtual Reality and Computerized Cognitive Intervention for Mild Cognitive Impairment in Heart Failure Vita, Com, Vita+Com - Heart Failure, Mild Cognitive Impairment | Not applicable | Active not recruiting | Indiana University | 172 | 2023-04-03 | 2026-03-23 |
Showing 20 of 186. Sign in to see all of them.
Lymphoma (32) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (27) · Leukemia (26) · Lymphoma, Non-Hodgkin (18) · Sarcoma (17) · Leukemia, Myeloid, Acute (16) · Hematologic Neoplasms (12) · Hodgkin Disease (11) · Myelodysplastic Syndromes (11) · Neoplasms (11) · Neuroblastoma (11) · Breast Neoplasms (9) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9) · Burkitt Lymphoma (8)
M.D. Anderson Cancer Center (30) · St. Jude Children's Research Hospital (19) · Children's Oncology Group (14) · National Cancer Institute (NCI) (11) · Northwestern University (10) · Memorial Sloan Kettering Cancer Center (8) · Baylor College of Medicine (7) · Masonic Cancer Center, University of Minnesota (6) · Dana-Farber Cancer Institute (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Center for International Blood and Marrow Transplant Research (2) · City of Hope Medical Center (2) · Columbia University (2) · Indapta Therapeutics, INC. (2)
United States (161) · Canada (19) · Australia (14) · Puerto Rico (8) · Switzerland (7) · Germany (6) · New Zealand (6) · United Kingdom (5) · Netherlands (3) · Belgium (2) · China (2) · Czechia (2) · France (2) · Israel (2) · Italy (2)
Richard Burt, MD (10) · Brandon Triplett, MD (4) · Aimee C. Talleur, MD (2) · Christopher G Kanakry, M.D. (2) · George Somlo, MD (2) · Izidore S. Lossos, MD (2) · Mengzhao Wang, MD (2) · Paul J. Petruska, MD (2) · Paul Szabolcs, MD (2) · Richard E. Champlin, MD (2) · Robert Krance, MD (2) · Saroj Vadhan-Raj, MD (2) · Steven Devine, MD (2) · Swati Naik, MBBS (2)
PMID 33735476, PMID 10076722, PMID 10080612, PMID 10458221, PMID 10499612, PMID 11426549, PMID 11464889, PMID 11600602, PMID 12101494, PMID 12932669, PMID 1310103, PMID 15042678, PMID 16204011, PMID 16226617, PMID 16293867, PMID 16421418, PMID 16446334, PMID 1648142, PMID 16556894, PMID 16809737, PMID 16943538, PMID 17075123, PMID 17873178, PMID 18802150, PMID 19468030, PMID 19648788, PMID 19760772, PMID 19826132, PMID 19994492, PMID 20038221, PMID 20049927, PMID 20572040, PMID 20637881, PMID 20660832, PMID 21454450, PMID 2156418, PMID 21632855, PMID 21873334, PMID 23065953, PMID 23091101, PMID 23167406, PMID 23664013, PMID 24028306, PMID 24957163, PMID 25682595, PMID 25909710, PMID 26009261, PMID 26199392, PMID 26260306, PMID 2824710
U10CA180886 (3), P30CA033572 (2), U10CA098543 (2), 2016 (1), 2025 (1), K76AG074940 (1), P30CA016672 (1), P30CA043703 (1), R01CA187076 (1), U10CA031946 (1), U10CA180820 (1), U10HL069294 (1), U24CA076518 (1), UM1AI109565 (1)